tbuckley/cabot-search huggingface dataset:
Another Diploma Mill in Wisconsin.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Importation of Wild Poliovirus Into Qinghai Province— China, 1999
Journal: JAMA (2000)

Indigenous wild poliovirus was last isolated in China in 1994. On October 13, 1999, a case of acute flaccid paralysis (AFP) in a 16-month-old boy was reported to public health authorities in Xunhua Autonomous County, Haidong Prefecture, Qinghai Province, China. Following onset of paralysis on October 12, the boy was no longer able to stand or walk. Two stool samples, taken within 14 days of onset of paralysis, were analyzed in the Qinghai provincial laboratory and yielded poliovirus. The isolates were later differentiated as wild poliovirus type 1 at the National Poliovirus Laboratory in Beijing. Stool specimens from one of five children with whom the boy had contact yielded wild poliovirus type 1. This report describes this case of poliomyelitis and the public health response to the case in China.
Bladder Cancers Respond to EGFR Inhibitors
Journal: Cancer Discovery (2014)

Abstract Researchers have discovered that nearly 25% of muscle-invasive bladder cancers fall into a “basal-like” subgroup that overexpresses EGFR and other proteins in the same pathway. EGFR inhibitors like erlotinib and cetuximab are effective against basal-like cell lines and tumors implanted into mice, arguing for clinical trials of the drugs for patients with this cancer subtype.
An Unusual Case of Carbon Monoxide Poisoning
Authors: Pierre L. Auger, Benoit Levesque, Richard Martel, Henri Prud'homme, David Bellemare, Claude Barbeau, Pierre Lachance, Marc Rhainds
Journal: Environmental Health Perspectives (1999)

Carbon monoxide, a gas originating from incomplete combustion of carbon-based fuels, is an important cause of human deaths. In this paper, we describe an unusual carbon monoxide poisoning in a dwelling without obvious sources of combustion gases, for which two adults had to be treated in a hyperbaric chamber. Carbon monoxide readings were taken in the house and in the neighboring homes. Methane gas and nitrogen oxide levels were also monitored in the house air. Soil samples were collected around the house and tested for hydrocarbon residues. The investigation revealed the presence of a pocket of carbon monoxide under the foundation of the house. The first readings revealed carbon monoxide levels of 500 ppm in the basement. The contamination lasted for a week. The investigation indicated that the probable source of contamination was the use of explosives at a nearby rain sewer construction site. The use of explosives in a residential area can constitute a major source of carbon monoxide for the neighboring populations. This must be investigated, and public health authorities, primary-care physicians, governmental authorities, and users and manufacturers of explosives must be made aware of this problem.
The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.
Authors: R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall, J. J. M. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots, R. A. Bender, J. Capdevila
Journal: Journal of Clinical Oncology (2011)

TPS167 Background: An 18-gene expression profile, ColoPrint, has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy. The gene signature has been validated in independent cohorts of 206 CC patients and in in-silico datasets (Salazar et al, JCO 2010). The profile classified 63.2% of the stage II patients (n=134) as Low Risk. The Hazard Ratio for relapse free survival (RFS) was 3.34 (p=0.017) with a 5-year RFS rate of 91% (95%CI, 84-98%) for Low Risk patients and 74% (95%CI, 59-89%) for High Risk patients. Moreover, the profile stratified patients independent of ASCO clinical risk factors. Methods: A prospective trial, PARSC (Prospective study for the Assessment of Recurrence risk in Stage II CC patients) using ColoPrint has been initiated. The main objectives are: Determine risk assessment by ColoPrint profile versus clinical parameters based on local protocol and ASCO high-risk recommendations in stage II patients Establish proportion of “good prognosis” and “poor prognosis profile” in various countries Validate the power of risk assessment and compare performance of ColoPrint and clinical risk assessment in estimating 3 year relapse rate. Inclusion criteria: age ≥ 18 years, adenocarcinoma of the colon, stage II, any neo-adjuvant therapy, no synchronous tumors, fresh tumor sample, and written informed consent. The treatment of the patient is at the discretion of the physician but should include a regimen containing a fluorinated pyrimidine. Results: The trial started in Sept. 2008 with currently 26 participating sites in 11 countries. Thus far, 262 stage 2 patients have been enrolled of whom 214 are eligible. 19 patients did not fulfill the inclusion criteria, and 29 patients were rejected based on low tumor content of the sample (<30% tumor cells). An interim analysis will be performed after 300 eligible stage 2 patients have been enrolled. Conclusion: The aim is to enroll 600 stage II patients to differentiate between 3 year RFS predicted by ColoPrint and clinical factors.
Incompatibilities in Prescription.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radiology, Detroit
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Understanding tendinopathies: Figure 1
Authors: G A Murrell
Journal: British Journal of Sports Medicine (2002)

O ne of the "banes" of most health professionals who look after athletes and workers is tendinopathies.What causes them?What gets them better?Recently there have been several advances that may contribute to our understanding of these disorders.We all know that tendinopathies occur in the tendinous portion of musculotendinous units that cross joints, often two joints-for example, the extensor carpi radialis brevis in tennis elbow, the patellar tendon in jumpers knee-and that they occur in situations of repetitive, high, often eccentric loading.The classic pathology is a loss of the normal collagenous architecture and replacement with an amorphous mucinous material that lacks the parallel, longitudinal architecture of normal tendon. 1 Soslowsky et al 2 made a major advance when they developed an animal model that could reproduce many of the microscopic changes of supraspinatus tendinopathy.The model involved running rats on a treadmill for up to an hour a day for 4-16 weeks.Supraspinatus tendons in the exercised animals had an increase in cellularity and loss of their normal collagen fibre organisation.The tendons were
THE PROPHYLAXIS OF FOURTH OF JULY TETANUS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Compensation Conundrums
Authors: Eaton M. MacKay
Journal: JAMA (1964)

<h3>To the Editor:—</h3> In the editorial, "Compensation Conundrums" (<i>JAMA</i><b>186</b>:254 [Oct 19] 1963), a communication by Drs. E. M. Krusen and D. E. Ford, "Compensation Factor in Low Back Injury" (<i>JAMA</i><b>166</b>: 1128 [March 8] 1958), is used as a basis for discussion. In this paper, as well as in the editorial, their study is interpreted to show that patients with compensable low back injuries recover more slowly and less often than patients with somewhat similar but noncompensable injuries. Such a conclusion is not warranted from their data. The compensation and noncompensation groups of Krusen and Ford cannot be compared for the following reasons: Variation in time after injury that the patients were referred for treatment does not allow valid comparison. The groups are not balanced so far as sex is concerned. Even if they were balanced for sex, there would have to be consideration of whether a
BOOK REVIEW
Authors: P. C. ALBERTSEN
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article BOOK REVIEW Get access Preventing Prostate Cancer: Screening Versus Chemoprevention , R. T. D. Oliver , A. Belldegrun , P. F. M. Wrigley , guest editors. Plainview, NY : Cold Spring Harbor Laboratory Press , 1995 . 350 pp., illus. $75. ISBN 0-87969-466-1 PETER C. ALBERTSEN, M.D. PETER C. ALBERTSEN, M.D. Department of Surgery, University of Connecticut Health Center263 Farmington Ave. Farmington, CT 06030-3955 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 22, 15 November 1995, Page 1714, https://doi.org/10.1093/jnci/87.22.1714 Published: 15 November 1995
AFL-CIO Fact Sheet on Chiropractic
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiovascular Disease in Diabetes
Authors: Zachary T. Bloomgarden
Journal: Diabetes Care (2008)

Perspectives on the News commentaries are part of a free monthly CME activity.The Mount Sinai School of Medicine, New York, New York, designates this activity for 2.0 AMA PRA Category 1 credits.If you wish to participate, review this article and visit www.diabetes.procampus.
Highlights
Journal: JAMA Pediatrics (2016)

Antidepressant Use During Pregnancy and the Risk of Autism 117There is continued confusion regarding the appropriate use of antidepressants during pregnancy.Boukhris and colleagues study 145 456 infants and their mothers' pregnancies.Use of antidepressants during pregnancy was associated with a 75% greater risk of autism spectrum disorder, even after adjusting for maternal history of depression.The accompanying editorial by King discusses the need to balance the benefi ts of treating maternal depression during pregnancy with the increased risk of autism in their off spring.
The Diseases of Children's Teeth, their Prevention and Treatment. A Manual for Medical Practitioners and Students.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study
Authors: P. W. Wilson
Journal: JAMA (1994)

<h3>Objective.</h3> —To describe the association between apolipoprotein E alleles (ε<i>2</i>, ε<i>3</i>, and ε<i>4</i>), dyslipidemias, and coronary heart disease (CHD). <h3>Design.</h3> —Cross-sectional prevalence study. <h3>Setting and Participants.</h3> —Community-based sample of men (n=1034) and women (n=916) aged 40 to 77 years who are participating in a long-term study of cardiovascular disease. Study participants underwent fasting lipid measurements, coronary risk factor determinations, and a comprehensive evaluation for the presence of current or previous CHD. <h3>Results.</h3> —Compared with the ε<i>3</i>allele, the ε<i>4</i>allele was associated with elevated low-density lipoprotein cholesterol values (≥4.14 mmol/L [160 mg/dL]) in women, the ε<i>2</i>and ε<i>4</i>alleles were associated with moderately elevated triglyceride values (≥2.82 mmol/L [250 mg/dL]) in men, and the ε2 allele was associated with severely elevated triglyceride values (≥5.64 mmol/L [500 mg/dL]) in men. The apolipoprotein E alleles were not associated with hypertension, obesity, smoking, or diabetes, but the ε<i>4</i>allele frequency was reduced in women after 60 years of age. The age-adjusted prevalence of CHD was associated with the ε<i>4</i>allele in both men (relative odds=1.53,<i>P</i>=.04) and women (relative odds=1.99,<i>P</i>=.05). In analyses for women and for both sexes combined, this relation persisted after adjustment by hypertension, smoking, obesity, diabetes, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. <h3>Conclusions.</h3> —Apolipoprotein E alleles are important genetic markers for dyslipidemia and CHD. The estimated CHD odds associated with the ε<i>4</i>allele appears to be greater than that for any other known genetic lipid abnormality, and the association of the ε<i>4</i>allele with CHD remains significant in women and both sexes combined after adjustment by traditional coronary risk factors and lipids. (<i>JAMA</i>. 1994;272:1666-1671)
PTU-073 Efficacy and safety of granulocyte, monocyte/macrophage adsorptive apheresis in steroid-dependent active uc with insufficient response or intolerance to immunosuppressants and/or biological therapies -the art trial: 24 and 48 week results
Authors: A Akbar, A Dignass, B Bonaz
Journal: Gut (2015)

<h3>Introduction</h3> Current medical options for patients with steroid-dependent, chronic-active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants +/- biologicals are limited. This study intended to generate further clinical data on efficacy and identify subpopulations of this difficult-to-treat UC population that would benefit from Granulocyte, Monocyte/Macrophage adsorptive (GMA) apheresis (Adacolumn®). <h3>Method</h3> This open-label, multicenter trial was conducted in the UK, France and Germany. 86 consecutive eligible patients (age 18–75) with steroid-dependent active UC (clinical activity index (CAI) ≥6 and Endoscopic Activity Index (EAI) ≥4), and insufficient response or intolerance to immunosuppressants (IS) +/- biologicals were included. Patients received up to 8 GMA aphereses in a single induction series on a weekly basis. Primary endpoint was remission (CAI ≤4) at Week 12; secondary efficacy parameters included clinical response (reduction in CAI ≥3), and steroid-free remission and response rates in the Intention-to-treat (ITT) population. Concomitant medication changes were recorded. 48 weeks results were analysed using the conservative approach. An analysis of sustained remission and sustained response, defined as the respective event observed at Week 12, and at Week 24, and at Week 48, was also performed. <h3>Results</h3> In the ITT 85 patients, response rates were 55.95% at week 12, 46.4% at week 24 and 39.3% at week 48. Remission rates were 39.29% at week 12, 34.5% at week 24 and 33.3% at week 48. In 30 patients with prior failure of IS and biologicals, 33.3% were in remission in week 24 and 20% at week 48. Steroid-free remission at week 24 was achieved by 19%, and 15.5% at week 48. Sustained remission or response was seen in 29.8% at 48 weeks. Concomitant IS medication was kept stable, steroid dose equivalents could be reduced, and quality of life improved through to week 48. 30 patients (41.7%) experienced at least 1 AE. 15 subjects experienced SAEs through to Week 48, none considered related to study treatment. Headache was the most prominent AE (21.2% of patients.) No new safety signals were seen. <h3>Conclusion</h3> This study describes a cohort of steroid-dependent moderate to severe active UC patients with intolerance to IS and/or biologicals in which treatment with GMA apheresis induction therapy was safe and effective. Benefit was seen in more than 50% of patients at Week 12, in 46.4% at Week 24 and in 39.3% at Week 48. <h3>Disclosure of interest</h3> A. Akbar Speaker Bureau of: lecturer fees from Otsuka, A. Dignass Grant/ Research Support from: Investigator fees from Otsuka, Speaker Bureau of: Lecturer fees from Otsuka, B. Bonaz Grant/ Research Support from: Investigator fees from Otsuka, Speaker Bureau of: lecturer fees from Otsuka.
Treatment of a pancreatic endocrine tumor by ethanol injection guided by endoscopic ultrasound
Authors: N. Muscatiello, A. Salcuni, L. Macarini, M. Cignarelli, S. Prencipe, M. di Maso, M. Castriota, V. D’Agnessa, E. Ierardi
Journal: Endoscopy (2008)

We report the case of a female patient with double endocrine neoplasia type 1. Echoendoscopy (EUS) revealed two nodular hypoechoic lesions ([Fig. 1]), with a color Doppler hypervascular pattern located in the pancreas. We carried out an EUS-guided fine-needle aspiration (FNA) biopsy [1] ([Fig. 2]), which showed a neuroendocrine islet tumor in the pathology report 2 weeks later. Tumor sizes were 11 and 7 mm respectively.
Gastrointestinal Angiography
Authors: Martin W. Donner
Journal: JAMA (1973)

Over the past few years, visceral angiography has emerged as an increasingly important diagnostic technique in clinical radiology. It is therefore timely that two competent experts in this field have written a comprehensive text dealing with the current knowledge of gastrointestinal angiography. The first chapter presents a thorough discussion of the equipment and techniques used in catheterization of the visceral arteries. The "real howto-do-it" and pitfalls of catheterization are discussed, followed by a section on the anatomy and common variations of the mesenteric vascular system. In additional chapters, the authors discuss the angiographic abnormalities of a variety of vascular diseases, tumors, posttraumatic conditions, inflammatory disease and cirrhosis, and portal hypertension. Newer techniques of pharmacoangiography, both for general diagnosis and control of gastrointestinal bleeding, are presented, as well as the uses of angiography in demonstrating the site of gastrointestinal hemorrhage. The illustrations for each chapter are well chosen and of particularly